British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010

HIV Medicine

Volumn 11, Issue 1, 2010, Pages 1-30

  Brook, G ^a   Main, J ^a   Nelson, M ^a   Bhagani, S ^a   Wilkins, E ^a   Leen, C ^a   Fisher, M ^a   Gilleece, Y ^a   Gilson, R ^a   Freedman, A ^a   Kulasegaram, R ^a   Agarwal, K ^a   Sabin, C ^a   Deacon Adams, C ^a  

^a BHIVA Secretariat Mediscript Ltd   (United Kingdom)

Author keywords

Guidelines; Hepatitis B; Hepatitis C; HIV; Treatment

Indexed keywords

ABACAVIR; ADEFOVIR; ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENTECAVIR; HEPATITIS A VACCINE; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS C ANTIBODY; HEPATITIS E ANTIBODY; INTERFERON; LAMIVUDINE; NEVIRAPINE; REBETRON; RIBAVIRIN; RITONAVIR; STAVUDINE; TELBIVUDINE; TENOFOVIR; TIPRANAVIR; UNINDEXED DRUG; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CD4 LYMPHOCYTE COUNT; CONDOM; COUNSELING; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG ACTIVITY; DRUG CONTRAINDICATION; DRUG MEGADOSE; DRUG POTENTIATION; ELASTOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; GENOTYPE; HARM REDUCTION; HEALTH CARE MANAGEMENT; HEALTH EDUCATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOBLOTTING; INFECTION PREVENTION; INTRAVENOUS DRUG ABUSE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER FIBROSIS; LIVER TOXICITY; LOW DRUG DOSE; MIXED INFECTION; MORBIDITY; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAFE SEX; SCREENING TEST; SEROCONVERSION; SEROLOGY; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; UNITED KINGDOM; VIRUS TRANSMISSION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CHILD; EVIDENCE-BASED MEDICINE; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HEPATITIS D; HEPATITIS VIRUSES; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY, ACTIVE; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE;

EID: 72449166927     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00781.x     Document Type: Article

References (239)

1. Giraudon I, Ruf M, Maguire H. Increase in diagnosed newly acquired hepatitis C in HIV positive men who have sex with men across London and Brighton, 2001-2006: is this an outbreak? Sex Transm Infect 2008, 84:111-115.
2. van de Laar T, Pybus O, Bruisten S. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology 2009, 136:1609-1617.
3. Danta M, Brown D, Bhagani S. Recent epidemic of acute hepatitis C Virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007, 21:983-991.
4. Danta M, Dusheiko G. Acute HCV in HIV-positive individuals - a review. Curr Pharmaceut Design 2008, 14:1690-1697.
5. Sanchez J, Gotuzzo E, Escamilla J. Sexually transmitted infections in female sex workers: reduced by condom use but not by a limited periodic examination programme. Sex Trans Dis 1998, 25:82-89.
6. Bhave G, Lindan CP, Hudes ES. Impact of an intervention on HIV, sexually transmitted diseases and condom use among sex workers in Bombay. AIDS 1995, 9((Suppl 1)):S21-S30.
7. Tanaka M, Nakayama H, Sakumoto M. Trends in sexually transmitted diseases and condom use patterns among commercial sex workers in Fukuoka City, Japan 1990-93. Genitourin Med 1996, 72:358-361.
8. Stewart T, Crofts N. An outbreak of hepatitis A among homosexual men in Melbourne. Med J Aust 1993, 158:519-521.
9. Reintjes R, Bosman A, de Zwart O. Outbreak of hepatitis A in Rotterdam associated with visits to 'darkrooms' in gay bars. Comm Dis Pub Health 1999, 2:43-46.
10. Bell A, Ncube F, Hansell A. An outbreak of hepatitis A among young men associated with having sex in public venues. Comm Dis Pub Health 2001, 4:163-170.
11. Mansson AS, Moestrup T, Nordenfelt E. Continued transmission of hepatitis B and C viruses, but no transmission of human immunodeficiency virus amongst inatravenous drug users participating in a syringe/needle exchange program. Scand J Infect Dis 2000, 32:253-258.
12. Amundsen EJ, Eskild E, Stigum H. Legal access to needles and syringes/needle exchange programmes versus HIV counselling and testing to prevent transmission of HIV among intravenous drug users. Eur J Pub Health 2003, 13:252-258.
13. Seal KH, Kral AH, Lorvick J. A randomized controlled trail of monetary incentives vs outreach to enhance the adherence to the hepatitis B vaccine series among injection drug users. Drug Alcohol Depend 2003, 71:127-131.
14. Borg L, Khuri E, Melia D. Methadone-maintained former heroin addicts, including those who are anti-HIV-1 seropositive, comply with and respond to hepatitis B vaccination. Addiction 1999, 94:489-493.
15. Veiga AP, Casseb J, Duarte AJ. Humoral response to hepatitis B vaccination and its relationship with T CD45RA+ (naive) and CD45RO+ (memory) subsets in HIV-1-infected subjects. Vaccine 2006, 24:7124-7128.
16. Francis DP, Hadler SC, Thompson SE. The prevention of hepatitis B with vaccine. Report of the Centers for Disease Control multi-center efficacy trial among homosexual men. Ann Int Med 1982, 97:362-366.
17. Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC. What level of hepatitis B antibody is protective? J Infect Dis 1999, 179:489-492.
18. Wong EK, Bodsworth NJ, Slade MA, Mulhall BP, Donovan B. Response to hepatitis B vaccination in a primary care setting: influence of HIV infection, CD4+ lymphocyte count and vaccination schedule. Int J STD AIDS 1996, 7:490-494.
19. Rey D, Krantz V, Partisani M. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine 2000, 18:1161-1165.
20. Brook MG, Rubinstein L, King G. Hepatitis B testing and vaccination in patients recently diagnosed with HIV infection. Int J STD AIDS 2008, 19:83-84.
21. Fonseca MO, Pang LW, de Paula Cavalheiro N. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005, 23:2902-2908.
22. Gandhi RT, Wurcel A, Lee H. Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis 2005, 191:1435-1441.
23. Geretti AM, Brook G, Cameron C. British HIV Association guidelines for immunization of HIV-infected adults 2008. HIV Med 2008, 9:795-848.
24. Bianco E, Stroffolini T, Spada E. Case fatality rate of acute viral hepatitis in Italy: 1995-2000. An update. Dig Liver Dis 2003, 35:404-408.
25. Willner IR, Uhl MD, Howard SC, Williams EQ, Riely CA, Waters B. Serious hepatitis A: an analysis of patients hospitalized during an urban epidemic in the United States. Ann Int Med 1998, 128:111-114.
26. Lok A, McMahon BJ. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Chronic hepatitis B. Hepatology 2001, 34:1225-1239.
27. Chevillotte G, Durbec JP, Gerolami A. Interaction between hepatitis B virus and alcoholic consumption in liver cirrhosis: an epidemiological study. Gastroenterology 1983, 85:141-145.
28. Mehta SH, Lau B, Afdhal NH, Thomas DL. Exceeding the limits of liver histology markers. J Hepatol 2009, 50:36-41.
29. Vergniol J, Foucher J, Castera L. Changes of non-invasive markers and FibroScan values during HCV treatment. J Viral Hepat 2009, 16:132-140.
30. Cappell MS, Schwartz MS, Biempica L. Clinical utility of liver biopsy in patients with serum antibodies to the human immunodeficiency virus. Am J Med 1990, 88:123-130.
31. Sulkowski MS, Mehta SH, Torbenson MS. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS 2007, 21:2209-2216.
32. Nguyen-Khac E, Capron D. Noninvasive diagnosis of liver fibrosis by ultrasonic transient elastography (Fibroscan). Eur J Gastroenterol Hepatol 2006, 18:1321-1325.
33. Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 2007, 102:2589-2600.
34. Friedrich-Rust M, Ong M. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008, 134:960-974.
35. Paggi S, Colli A, Fraquelli M. A non-invasive algorithm accurately predicts advanced fibrosis in hepatitis C: a comparison using histology with internal-external validation. J Hepatol 2008, 49:564-571.
36. Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality. J Cell Mol Med 2007, 11:1031-1051.
37. Labarga P, Soriano V, Vispo ME. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007, 196:670-676.
38. Phillips E, Gutiérrez S, Jahnke N. Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients. AIDS 2007, 21:1561-1568.
39. Gonzalez de Requena D, Nunez M, Jimenez-Nacher I, Soriano V. Liver toxicity caused by nevirapine. AIDS 2002, 25:290-291.
40. Macǐas J, Castellano V, Merchante N. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS 2004, 18:767-774.
41. Mocroft A, Rockstroh J, Soriano V. Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection? Antivir Ther Lond 2005, 10:779-790.
42. Sulkowski MS, Mehta SH, Torbenson M. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005, 19:585-592.
43. McGovern BH, Ditelberg JS, Taylor LE. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis 2006, 43:365-372.
44. Maida I, Garcia-Gasco P, Sotgiu G. Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome. Antivir Ther 2008, 13:103-107.
45. Chan-Tack KM, Struble KA, Birnkrant DB. Intracranial hemorrhage and liver-associated deaths associated with tipranavir/ritonavir: review of cases from the FDA's Adverse Event Reporting System. AIDS Patient Care Stds 2008, 22:843-850.
46. Vispo E. Warning on hepatotoxicity of darunavir. AIDS Rev 2008, 10:63.
47. Rosenthal E, Poiree M, Pradier C. Mortality due to hepatitis-C related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 2003, 17:1803-1809.
48. Merchante N, Giron-Gonzalez J, Gonzalez-Serrano M. Survival and prognostic factors of HIV-infected patients with HCV-related end stage liver disease. AIDS 2006, 20:49-57.
49. Merchante N, Jimenez-Saenz M, Pineda J. Management of HCV-related end-stage liver disease in HIV-coinfected patients. AIDS Rev 2007, 9:131-139.
50. Garcia-Samaniego J, Rodriguez M, Berenguer J. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001, 96:179-183.
51. Puoti M, Bruno R, Soriano V. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation, and outcomes. AIDS 2004, 18:2285-2293.
52. Brau N, Fox R, Xiao P. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicentre study. J Hepatol 2007, 47:527-537.
53. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
54. Chen J, Yang HI, Su J. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA levels. JAMA 2006, 295:65-73.
55. Clifford G, Rickenbach M, Polesel J. Influence of HIV-related immunodef iciency on the risk of hepatocellular carcinoma. AIDS 2008, 22:2135-2141.
56. El-Sarag H, Marremo J, Lenhard R, Reddy R. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008, 135:1752-1763.
57. Zhang BH, Yang BH, Tang JY. Randomised controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004, 130:417-422.
58. Soriano V, Miro J, Garcia-Smaniego J. Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. J Viral Hepat 2004, 11:2-17.
59. O'Grady J, Taylor C, Brook G. Guidelines for liver transplantation in patients with HIV infection (2005). HIV Med 2005, 6((Suppl 2)):149-153.
60. Roland M, Stock P. Liver transplantation in HIV-infected recipients. Semin Liver Dis 2006, 26:273-284.
61. Terrault N, Carter J, Carlson L. Outcome of patients with HBV and HIV infections referred for liver transplantation. Liver Transpl 2006, 12:801-807.
62. Joshi D, Aluvihare V, Belgaumkar A. Liver transplantation for HIV: analysis of outcomes suggest HIV/HCV co-infected patients have prohibitively poor survival at 5 years. , San Francisco, October 2008 [Abstract 6]
63. Miro JM, Aguero F, Laguno M. Liver transplantation in HIV/hepatitis co-infection. J HIV Ther 2007, 12:24-35.
64. Mindikoglu AL, Reger A, Magder LS. Impact of human immunodeficiency virus on survival after transplantation; analysis of United Network for Organ Sharing database. Transplantation 2008, 85:359-368.
65. Duclos-Vallee JC, Feray C, Sebhag M. Survival and recurrence of hepatitis C after liver transplantation in patients co-infected with human immunodeficiency virus and hepatitis C. Hepatology 2008, 47:407-417.
66. Miro J, Montejo M, Castells L. 5-year survival of HCV/HIV co-infected liver transplant recipients: a case-control study. In: Programme and abstracts, . Montreal, Canada, February 2009 [Abstract P833]
67. Suddle A, Aluvihare V, Muiesan P. Long Term Outcomes in Non-Heart Beating Donor Grafts in Liver Transplantation for Chronic Hepatitis C: no increase in HCV recurrence or graft loss. . San Francisco, October 2008 [Abstract 596]
68. Moreno A, Barcena R, Del Campo S. Effect of HIV co-infection on the outcome of viral cirrhosis liver transplant candidates on the waiting list at a reference centre 2001-2008. In: Programme and abstracts, . Montreal, Canada, February 2009 [Abstract P835]
69. http://www.who.int/mediacentre/factsheets/fs204/en/, WHO., Hepatitis B. Fact sheet No. 204 Aug 2008. Available at, (accessed 22 October 2008)
70. http://data.unaids.org/pub/GlobalReport/2008/jc1510_2008_global_report_pp211_234_en.pdf, UNAIDS., 2008 Report on the global AIDS epidemic: HIV and AIDS estimates and data 2001 and 2007. Available at, (accessed 22 October 2008)
71. Benhamou Y. Hepatitis B in the HIV-coinfected patient. JAIDS 2007, 45((Suppl 2)):S57-S65. and S66-S67
72. Konopnicki D, Mocroft A, de Wit S. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005, 19:593-601.
73. de Silva S, Brook MG, Curtis H, Johnson M. Survey of HIV and hepatitis B or C co-infection management in the UK 2004. Int J STD AIDS 2006, 17:799-801. on behalf of the British HIV Association Audit Committee.
74. Firnhaber C, Reyneke A, Schulze D. The prevalence of hepatitis B co-infection in a South African urban government HIV clinic. South African Med J 2008, 98:541-544.
75. Nyirenda M, Beadsworth MB, Stephany P. Prevalence of infection with hepatitis B and C virus and coinfection with HIV in medical inpatients in Malawi. J Infection 2008, 57:72-77.
76. http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1203084368853, Health Protection Agency., HIV data: Black Africans and Black Caribbeans: 2007 Black African and black Caribbean Summary Statistics. Available at, (accessed 23 September 2009).
77. Opravil M, Hunziker R, Luthy R. Chronic hepatitis B and C in HIV infected patients. Deutsche Med Wochensch 1998, 123:753-760.
78. Piroth L, Sene D, Pol S. Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY). AIDS 2007, 21:1323-1331.
79. Jain MK, Parekh NK, Hester J, Lee WM. Aminotransferase elevation in HIV/hepatitis B virus co-infected patients treated with two active hepatitis B virus drugs. AIDS Patient Care STDS 2006, 20:817-822.
80. Hoffmann CJ, Charalambous S, Thio CL. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 2007, 21:1301-1308.
81. Omland LH, Weis N, Skinhøj P. Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study. HIV Med 2008, 9:300-306.
82. Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991, 163:1138-1140.
83. Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 2006, 44((Suppl)):S65-S70.
84. Thio CL. Hepatology 2009, 49((Suppl)):S138-S145. Hepatitis B and human immunodeficiency virus coinfection
85. Marcellin P, Pequignot F, Delarocque-Astagneau E. Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol 2008, 48:200-207.
86. Weber R, Sabin CA, Friis-Moller N. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Int Med 2006, 166:1632-1641.
87. Mai AL, Yim C, O'Rourke K. The interaction of human immunodeficiency virus infection and hepatitis B virus infection in homosexual men. J Clin Gastroenterol 1996, 22:299-304.
88. Sheng WH, Kao JH, Chen PJ. Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis 2007, 45:1221-1229.
89. Miailhes P, Trabaud MA, Pradat P. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. Clin Infect Dis 2007, 45:624-632.
90. Manegold C, Hannoun C, Wywiol A. Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2001, 32:144-148.
91. Nebbia G, Garcia-Diaz A, Ayliffe U. Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons. J Med Virol 2007, 79:1464-1471.
92. Hofer M, Joller-Jemelka HI, Grob PJ. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss cohort study. Eur J Clin Microbiol Infect Dis 1998, 17:6-13.
93. Martin-Carbonero L, Soriano V, Valencia E. Increased impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 2001, 17:1467-1471.
94. Pungpapong S, Kim WR, Poterucha JJ. Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin Proc 2007, 82:967-975.
95. IIoeje UH, Yang HI, Su J. Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130:678-686.
96. Chen CJ, Yang HI, Yeh SH. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 296:65-73. for the REVEAL-HBV Study Group.
97. Yuen MK, Ng IO, Fan ST. Significance of HBV DNA levels in liver histology of HBeAg and Anti-HBe positive patients with chronic hepatitis B. Am J Gastroenterol 2004, 99:2032-2037.
98. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007, 45:507-539.
99. EASL Clinical Practice Guidelines: management of chronic hepatitis. Br J Hepatol 2009, 50:227-242. European Association for the Study of Liver.
100. Carreno V, Rico MA, Pardo M, Quiroga JA. Extended follow-up of anti-HBe-positive patients with chronic hepatitis B retreated with ribavirin and interferon-alpha. Antivir Res 2001, 52:147-152.
101. Bonino E, Marcellin P, Lau GK. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007, 56:699-705. for the Pegintron Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group
102. Idilman R, Kaymakoglu S, Oguz Onder F. A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients. J Viral Hepat 2009, 16:279-285.
103. Pawlotsky JM. Virologic techniques for the diagnosis and monitoring of hepatitis B. Gastroenterol Clin Biol 2008, 32:S56-S63.
104. Papatheodoridis GV, Manesis EK, Manolakopoulos S. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection? Hepatology 2008, 48:1451-1459.
105. Giovanna F, Bortolotti F, Francesco D. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008, 48:335-352.
106. Lai CL, Yuen MF. The natural history of chronic hepatitis B. J Viral Hepat 2007, 14((Suppl 1)):6-10.
107. Stuyver L, van Geyt C, De Gendt S. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 2000, 38:702-707.
108. Lok AS, Zoulim F, Locarnini S. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol 2002, 40:3729-3734.
109. Zoulim F, Buti M, Lok AS. Antiviral-resistant hepatitis B virus: can we prevent this monster from growing? J Viral Hepat 2007, 14((Suppl 1)):29-36.
110. Zoulim F. New nucleic acid diagnostic tests in viral hepatitis. Semin Liver Dis 2006, 26:309-317.
111. Flink HJ, van Zonneveld M, Hansen BE. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B:HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006, 101:297-303. for the 99-01 Study Group
112. Yang HI, Yeh SH, Chen PJ. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008, 100:1134-1143. for the REVEAL-HBV Study Group
113. Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002, 36:1425-1430.
114. Erhardt A, Reineke U, Blondin D. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 2000, 31:716-725.
115. Kao JH, Chen PJ, Lai MY. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000, 118:554-559.
116. Tsubota AK, Arase Y, Ren FR. Genotype may correlate with liver carcinogenesis and tumor characteristics in cirrhotic patients infected with hepatitis B virus subtype adw. J Med Virol 2001, 65:257-265.
117. Pawlotsky JM, Dusheiko G, Hatzakis A. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 2008, 134:405-415.
118. European association for the study of the liver. J Hepatol 2009, 50:227-242. EASL Clinical Practice Guidelines: management of hepatitis B.
119. Soriano V, Puoti M, Peters M. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B virus international panel. AIDS 2008, 22:1399-1410.
120. Carosi G, Rizzeto M. Treatment of chronic hepatitis B: recommendations from an Italian workshop. Dig Liver Dis 2008, 40:603-617.
121. Rockstroh JK, Bhagani S, Benhamou Y. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008, 9:82-88.
122. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf, Panel on Antiretroviral Guidelines for Adults and Adolescents., Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3, 2008. Available at, (accessed 3 August 2009)
123. Sorrell MF, Belongia EA, Costa J. National Institutes of Health Consensus Development Conference Statement: management of Hepatitis B. Ann Int Med 2009, 150:104-110.
124. Gazzard B, Anderson A, Babiker A. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008, 9:563-608.
125. Johnson R, Ristig M, Overton E. Safety and tolerability of sequential pegylated IFN-alpha2a and tenofovir for hepatitis B infection in HIV+individuals. HIV Clin Trials 2007, 8:173-181.
126. Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis 2006, 26:142-152.
127. Peters MG, Andersen J, Lynch P. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006, 44:1110-1116.
128. Sheldon JA, Corral A, Rodes B. Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir. AIDS 2005, 19:2036-2038.
129. Lampertico P, Vigano M, Manenti E. Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007, 133:1445-1451.
130. McMahon M, Jilek B, Brennan T. The HBV drug entecavir - effects on HIV replication and resistance. N Engl J Med 2007, 356:2614-2621.
131. Dore GJ, Cooper DA, Barrett C. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). CAESAR Coordinating Committee. J Infect Dis 1999, 180:607-613.
132. Matthews G, Bartholomeusz A, Locarnini S. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006, 20:863-870.
133. Benhamou Y, Bochet M, Thibault V. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999, 30:1302-1306.
134. Benhamou Y, Fleury H, Trimoulet P. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 2006, 43:548-555.
135. Dore G, Cooper D, Pozniak A. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004, 189:1185-1192.
136. Matthews GV, Avihingsanon A, Lewin SR. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. Hepatology 2008, 48:1062-1069.
137. Jain MK, Comanor L, White C. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response. J Viral Hepat 2007, 14:176-182.
138. Bartholomeusz A, Locarnini S. Hepatitis B virus mutations associated with antiviral therapy. J Med Virol 2006, 78((Suppl 1)):S52-S55.
139. Kwon SY, Choe WH, Lee CH, Yeon JE, Byun KS. Rapid re-emergence of YMDD mutation of hepatitis B virus with hepatic decompensation after lamivudine retreatment. World J Gastroenterol 2008, 14:4416-4419.
140. Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008, 28:1067-1077.
141. Yoo BC, Kim JH, Chung YH. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2007, 45:172-178.
142. http://investor.pharmasset.com/releasedetail.cfm?ReleaseID=378789, Pharmasset Inc., Pharmasset voluntarily halts clinical studies with clevudine in hepatitis B infected patients. Available at, (accessed 12 May 2009)
143. Kumar M, Satapathy S, Monga R. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 2007, 45:97-101.
144. Kellerman SE, Hanson DL, McNaghten AD, Fleming PL. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis 2003, 188:571-577.
145. Hou J, Yin YK, Xu D. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology 2008, 47:447-454.
146. Cross TJS, Rizzi P, Horner M. The increasing prevalence of hepatitis delta virus (HDV) infection in South London. J Med Virol 2008, 80:277-282.
147. de Pouplana M, Soriano V, Samaniego JG, Enriquez A, Munoz F, Gonzalez-Lahoz J. More severe course of delta hepatitis in HIV-infected patients. Genitourin Med 1995, 71:132-133.
148. Sheng W, Hung C, Kao J. Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of HAART: a matched cohort study. Clin Infect Dis 2007, 44:988-995.
149. Manesis E, Schina M, Le Gal F. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring. Antivir Ther 2007, 12:381-388.
150. Niro GA, Ciancio A, Gaeta GB. Pegylated interferon alpha-2b monotherapy and in combination with ribavirin in chronic hepatitis delta. Hepatology 2006, 44:713-720.
151. Rosa I, Costes L, Garrait V, Chousterman M. Efficacy of pegylated interferon alpha-2b for the treatment of chronic delta hepatitis in a patient co-infected with HIV. AIDS 2005, 19:2177-2178.
152. Puoti M, Rossi S, Forleo MA. Treatment of chronic hepatitis D with interferon alpha-2b in patients with human immunodeficiency virus infection. J Hepatol 1998, 29:45-52.
153. Sheldon J, Ramos B, Toro C. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV/HBV/HDV co-infected patients? Antivir Ther 2008, 13:97-102.
154. http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1228894676145, Health Protection Agency., Hepatitis C in the UK. Available at, (accessed 24 December 2008)
155. Low E, Vogel M, Rockstroh J, Nelson M. Acute hepatitis C in HIV-positive individuals. AIDS Rev 2008, 10:245-253.
156. Richardson D, Fisher M, Sabin CA. Sexual transmission of hepatitis C in MSM may not be confined to those with HIV infection. J Infect Dis 2008, 197:1213-1214.
157. Turner J, Rider A, Imrie J. Behavioural predictors of subsequent hepatitis C diagnosis in a UK clinic sample of HIV positive men who have sex with men. Sex Transm Infect 2006, 82:298-300.
158. Ghosn J, Deveau C, Goulard C. Increase in hepatitis C virus incidence in HIV-1 infected patients followed up since primary infection. Sex Transm Infect 2006, 82:458-460.
159. Rauch A, Rickenbach M, Weber R. Unsafe sex and increased incidence of hepatitis C virus infection among HIV infected men who have sex with men: the Swiss HIV cohort study. Clin Infect Dis 2005, 41:395-402.
160. Cohen DF, Russell CJ, Golub SA, Mayer KH. Prevalence of hepatitis C infection among men who have sex with men at a Boston Community Health Centre and its association with markers of high-risk behaviour. AIDS Patient Care STDs 2006, 20:557-564.
161. Browne R, Asboe D, Gilleece Y. Increased numbers of acute hepatitis C infections in HIV positive homosexual men; is sexual transmission feeding the increase? Sex Transm Infect 2004, 80:326-327.
162. Greub G, Ledergerber B, Battegay M. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000, 356:1800-1805.
163. Antonucci G, Girardi E, Cozzi-Lepri A. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals. Clin Infect Dis 2005, 40:e101-e109.
164. Rockstroh JK, Mocroft A, Soriano V. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005, 192:992-1002. for the EuroSIDA Study Group
165. Lichterfeld M, Schmeisser N, Qurishi N. Clinical outcomes of HIV-HCV co-infection in a large cohort of hemophiliac patients. J Infect 2005, 50:221-228.
166. Stebbing J, Waters L, Mandalia S, Bower M, Nelson M, Gazzard B. Hepatitis C virus infection in HIV type 1-infected individuals does not accelerate a decrease in the CD4+ cell count but does increase the likelihood of AIDS-defining events. Clin Infect Dis 2005, 41:906-911.
167. Sullivan PS, Hanson DL, Teshale EH, Wotring LL, Brooks JT. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy. AIDS 2006, 20:1171-1179.
168. Mohsen AH, Easterbrook PJ, Taylor C. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 2003, 52:1035-1040.
169. Bonnard P, Lescure FX, Amiel C. Documented rapid course of hepatic fibrosis between two biopsies in patients coinfected by HIV and HCV despite high CD4 cell count. J Viral Hepat 2007, 14:806-811.
170. Darby SC Ewart D, Giangrande PL. Mortality from liver cancer and liver disease in haemophiliac men and boys in the UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet 1997, 350:1425-1431.
171. Rodríguez-Torres M, Rodríguez-Orengo JF, Ríos-Bedoya CF. Effect of hepatitis C virus treatment in fibrosis progression rate (FPR) and time to cirrhosis (TTC) in patients co-infected with human immunodeficiency virus: a paired liver biopsy study. J Hepatol 2007, 46:613-619.
172. Girón-González JA, Brun F, Terrón A, Vergara A, Arizcorreta A. Natural history of compensated and decompensated HCV-related cirrhosis in HIV-infected patients: a prospective multicentre study. Antivir Ther 2007, 12:899-907.
173. Pineda JA, García-García JA, Aguilar-Guisado M. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 2007, 46:622-630.
174. Cacoub P, Geffray L, Rosenthal E. Mortality among HIV-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases in 1995 and 1997. Clin Infect Dis 2001, 32:1207-1214.
175. Mocroft A, Brettle R, Kirk O. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002, 16:1663-1671. for the EuroSIDA study group
176. Smit C, Geskus R, Walker S. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006, 20:741-749. for the CASCADE Collaboration
177. Cribier B, Rey D, Schmitt C. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS 1995, 9:1131-1136.
178. Tedaldi E, Peters L, Neuhaus J. Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis 2008, 47:1468-1475.
179. Shores NJ, Maida I, Soriano V, Núnez M. Sexual transmission is associated with spontaneous HCV clearance in HIV-infected patients. J Hepatol 2008, 49:323-328.
180. Gilleece Y, Browne R, Asboe D. Transmission of hepatitis C virus among HIV positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. JAIDS 2005, 40:41-46.
181. Leurkemyer A, Bradley Hare C, Stansell J. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. JAIDS 2006, 41:31-36.
182. Gerlach JT, Diepolder HM, Zachoval R. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003, 125:80-88.
183. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999, 29:908-914.
184. Thomson EC, Nastouli E, Main J. Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. AIDS 2009, 23:89-93.
185. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology 2002, 36:S65-S73.
186. Montes RML, Rodriguez ZM. Report of three cases of hyperlactacidemia/lactic acidosis after treatment of hepatitis C with pegylated interferon and ribavirin in HIV coinfected patients. Rev Clin Esp 2002, 202:543-545.
187. Bani-Sadr F, Denoeud L, Morand P. Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role? JAIDS 2007, 45:123-125.
188. Bräu N, Rodriguez-Torres M, Prokupek D. Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin. Hepatology 2004, 39:989-998.
189. Bani-Sadr F, Carrat F, Pol S. Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy. JAIDS 2005, 4:47-52.
190. Mira JA, López-Cortés LF, Barreiro P. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother 2008, 62:1365-1373.
191. Amorosa V, Slim J, Mounzer K. Abacavir use is not associated with lack of virologic response in ARV-treated HIV/HCV-co-infected patients receiving pegylated interferon and ribavirin. . Montreal, Canada, February 2009 [Abstract 850]
192. Quereda C, Corral I, Moreno A. Effect of treatment with efavirenz on neuropsychiatric adverse events of interferon in HIV/HCV-coinfected patients. JAIDS 2008, 49:61-63.
193. Saadoun D, Resche-Rigon M, Sene D. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. Ann Rheumat Dis 2008, 67:1431-1436.
194. Shea DO, Tuite H, Farrell G. Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV/HIV co-infected individuals. J Viral Hepat 2008, 15:482-489.
195. Martin-Carbonero L, Nuñez M, Mariño A. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. AIDS 2008, 22:15-21.
196. Van den Eynde E, Crespo M, Estaban JI. Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial. Clin Infect Dis 2009, 48:1152-1159.
197. Martin-Carbonero L, Benhamou Y, Puoti M. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European Collaborative Study. Clin Infect Dis 2004, 38:128-133.
198. Verma S, Wang CH, Govindarajan S. Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients? Clin Infect Dis 2006, 42:262-270.
199. Qurishi N, Kreuzberg C, Luchters G. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003, 362:1708-1713.
200. Carrat F, Bani-Sadr F, Pol S. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004, 292:2839-2848.
201. Chung R, Anderson J, Volberding P. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004, 351:451-459.
202. Foster GR, Fried MW, Hadziyannis SJ, Messinger D, Freivogel K, Weiland O. Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin. Scand J Gastroenterol 2007, 42:247-255.
203. Castellares C, Barreiro P, Martin-Carbonero L. Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome. J Viral Hepat 2008, 15:165-172.
204. Evon DM, Verma A, Simpson K. Psychiatric symptoms during interferon treatment for hepatitis C: experiences from a tertiary care hepatology centre. Aliment Pharmacol Ther 2008, 27:1071-1080.
205. Heathcote EJ, Shiffman ML, Cooksley GE. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000, 343:1673-1680.
206. Mira JA, Lopez-Cortes LF, Merino D. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients. Antivir Ther 2007, 12:1225-1235.
207. Ho SB, Groessl E, Dollarhide A. Management of chronic hepatitis C in veterans: the potential of integrated care models. Am J Gastroenterol 2008, 103:1810-1823.
208. Sene D, Touitou V, Bodaghi B. Intraocular complications of IFN-alpha and ribavirin therapy in patients with chronic viral hepatitis C. World J Gastroenterol 2007, 13:3137-3140.
209. Andrade RJ, Gonzalez FJ, Vazquez L. Vascular ophthalmological side effects associated with antiviral therapy for chronic hepatitis C are related to vascular endothelial growth factor levels. Antivir Ther 2006, 11:491-498.
210. Nunez M, Miralles C, Berdun MA. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 2007, 23:972-982.
211. Nunez M, Ocampo A, Aguirrebengoa K. Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin. J Viral Hepat 2008, 15:363-369.
212. Squillace N, Lapadula G, Torti C. Hepatitis C virus antibody-positive patients with HIV infection have a high risk of insulin resistance: a cross-sectional study. HIV Med 2008, 9:151-159.
213. Chung R. SLAM-C (ACTG A5178): Role of early virologic response in extended therapy with PEG-interferon and weight-based ribavirin in HCV/HIV co-infection. . Montreal, February 8-11, 2009 [Abstract 103LB]
214. Crespo M, Mira JA, Pineda JA. Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen. J Antimicrob Chemother 2008, 62:793-796.
215. Basso M, Torre F, Grasso A. Pegylated interferon and ribavirin in re-treatment of responder-relapser HCV patients. Dig Liver Dis 2007, 39:47-51.
216. Ciancio A, Picciotto A, Giordanino C. A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin. Aliment Pharmacol Ther 2006, 24:1079-1086.
217. Giordanino C, Bugianesi E, Smedile A. Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study. Am J Gastroenterol 2008, 103:2481-2487.
218. Jensen DM, Freilich B, Andreone P. Pegylated interferon alfa-2a (40kd) plus ribavirin (RBV) in prior non-responders to pegylated interferon alfa-2b (12kd)/RBV: final efficacy and safety outcomes of the REPEAT study. . Boston, Massachusetts, November 2-6, 2007 [Abstract LB4]
219. Murphy AA, Rozenberg I, Polis MA. Twice-Weekly Peg IFN-alpha-2a with Ribavirin Improves Early Viral Kinetics over Standard Therapy among HIV/HCV Co-Infected African American Patients. . Washington, DC, October 25-28, 2008 [Abstract V-4220]
220. Everson GT, Hoefs JC, Seeff LB. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology 2006, 44:1675-1684.
221. Sherman K, Andersen J, Butt A. Sustained Long-term Antiviral Maintenance with Pegylated Interferon in HCV/HIV-co-infected Patients: Early Viral Response and Effect on Fibrosis in Treated and Control Subjects. . Boston, February 3-6, 2008 [Abstract 59]
222. Zeuzem S, Yoshida EM, Benhamou Y. Albinterferon alfa-2b dosed every two or four weeks in interferon-naive patients with genotype 1 chronic hepatitis C. Hepatology 2008, 48:407-417.
223. Stauber RE, Kessler HH. Drugs in development for hepatitis C. Drugs 2008, 68:1347-1359.
224. Roberts SK, Cooksley G, Dore GJ. Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology 2008, 48:398-406.
225. Gish RG. Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother 2006, 57:8-13.
226. Sheldon J, Barreiro P, Vincent V. Novel protease and polymerase inhibitors for the treatment of hepatitis C virus infection. Expert Opin Invest Drugs 2007, 16:1171-1181.
227. Liu-Young G, Kozal MJ. Hepatitis C protease and polymerase inhibitors in development. AIDS Patient Care Stds 2008, 22:449-457.
228. Gotz HM, van Doornum G, Niesters HG. A cluster of acute hepatitis C among men who have sex with men: results from contact tracing and public health implications. AIDS 2005, 19:969-974.
229. Bhagani S, Dante M, Huj C. Acute hepatitis C in a cohort of HIV positive men: outcomes and response to pegylated interferon-alfa 2b and ribavirin. BHIVA Spring Conference. Cardiff, April 15-17, 2004 [Abstract O20]
230. Danta M, Semmo N, Fabris P. Impact of HIV on host-virus interactions during early hepatitis C virus infection. J Infect Dis 2008, 197:1558-1566.
231. Soriano V, Mocroft A, Rockstroh J. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis 2008, 198:1337-1344. for the EuroSIDA Study Group
232. Fierer DS, Uriel AJ, Carriero DC. Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. J Infect Dis 2008, 198:683-686.
233. Matthews GV, Hellard M, Haber P. Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis 2009, 48:650-658.
234. Audagnotto S, De Rosa F, Bargiacchi O. Treatment of acute hepatitis in HIV infected patients. JAIDS 2005, 40:110-111.
235. Danta M, Turner J, Johnstone R. Use of pegylated interferon-alpha with or without ribavirin in the treatment of acute HCV in HIV-positive individuals. HIV Med 2005, 6((Suppl 1)):40.
236. Dominguez S, Ghosn J, Valantin M. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS 2006, 20:1157-1161.
237. Vogel M, Natterman J, Baumgarten A. Pegylated interferon-alpha for the treatment of sexually transmitted acute HCV-infection in HIV-positive individuals. Antivir Ther 2006, 11:1097-1101.
238. Kamal S, Fouly A, Kamel R. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 2006, 130:632-638.
239. Rodríguez-Nóvoa S, Morello J, González M. Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin. AIDS 2008, 22:2535-2537.